CSIMarket
 
Twist Bioscience Corporation  (TWST)
Other Ticker:  
 
 
Price: $33.6400 $-0.92 -2.662%
Day's High: $35.19 Week Perf: -8.74 %
Day's Low: $ 33.42 30 Day Perf: -15.58 %
Volume (M): 1,006 52 Wk High: $ 43.21
Volume (M$): $ 33,825 52 Wk Avg: $23.28
Open: $34.41 52 Wk Low: $11.46



 Market Capitalization (Millions $) 1,934
 Shares Outstanding (Millions) 58
 Employees 750
 Revenues (TTM) (Millions $) 262
 Net Income (TTM) (Millions $) -206
 Cash Flow (TTM) (Millions $) -50
 Capital Exp. (TTM) (Millions $) 17

Twist Bioscience Corporation
Twist Bioscience Corporation is a synthetic biology company that specializes in producing high-quality DNA strands for a wide range of applications. Headquartered in San Francisco, California, Twist Bioscience was founded in 2013 and has grown to become a leading player in the field of synthetic biology.

One of the primary focuses of Twist Bioscience is the production of synthetic DNA strands, which it sells to customers in the pharmaceutical, academic, and industrial sectors. The company uses a proprietary process to manufacture DNA strands, which allows it to produce large quantities of high-quality, double-stranded DNA quickly and inexpensively.

In addition to its core synthetic DNA business, Twist Bioscience also offers a range of other products and services. These include custom gene synthesis, which allows customers to design and order specific DNA sequences for use in research and development; NGS (Next-Generation Sequencing), which allows researchers to analyze large quantities of genomic data quickly and accurately; and CRISPR gene editing, which employs a revolutionary method for altering DNA sequences with precision.

Twist Bioscience's technology platform is based on a proprietary silicon-based microchip that is capable of synthesizing millions of different DNA strands simultaneously. The company's expertise in DNA synthesis and gene editing has opened up a wide range of potential applications, including drug discovery, genetic engineering, and precision medicine.

Twist Bioscience is well-positioned in the emerging field of synthetic biology, a rapidly growing area of biotechnology that seeks to engineer biological systems for specific applications. The company is backed by a strong team of scientific experts and experienced business leaders, and has raised significant funding from top-tier investors, including ARCH Venture Partners, Illumina, and Fidelity Investments.

In summary, Twist Bioscience is a cutting-edge synthetic biology company that specializes in DNA synthesis and gene editing. Its proprietary technology platform and expertise in the field of synthetic biology have opened up a range of exciting potential applications, and the company is well-positioned to continue to lead in this exciting and rapidly growing field.


   Company Address: 681 Gateway Blvd South San Francisco 94080 CA
   Company Phone Number: 719-0671   Stock Exchange / Ticker: NASDAQ TWST
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Product Service News

Twist Bioscience Boosts Genomics with IVDR-compliant Precision Dx Products for Whole Exome Sequencing

Published Tue, Mar 5 2024 1:00 PM UTC

Twist Bioscience Launches IVDR-compliant Precision Dx Products for Whole Exome SequencingSOUTH SAN FRANCISCO, Calif. - Twist Bioscience Corporation (NASDAQ: TWST), a leading company in synthetic DNA production using its silicon platform, announced the launch of its Twist Precision Dx next-generation sequencing (NGS) products that comply with the European Union (EU) in vitro ...

Stock Issue News

Twist Bioscience Employs Strategic Inducement Grants: Paving the Way for Future Triumphs

Published Wed, Feb 7 2024 1:00 PM UTC


In a recent press release, Twist Bioscience Corporation (NASDAQ: TWST), a leading provider of high-quality synthetic DNA using its innovative silicon platform, announced that it has granted a total of 122,400 restricted stock units (RSUs) to 36 newly hired employees. These grants were made in compliance with the rules of the Nasdaq Stock Market as an inducement to attra...

Product Service News

Revolutionizing Exome Sequencing: Twist Bioscience and Element Biosciences Collaborate to Enhance AVITI System

Published Tue, Feb 6 2024 1:05 PM UTC

In a groundbreaking collaboration, Twist Bioscience Corporation and Element Biosciences have joined forces to revolutionize exome sequencing and empower scientific advancements. Twist Bioscience, renowned for its state-of-the-art silicon platform that enables the synthesis of high-quality synthetic DNA, will be partnering with Element Biosciences, a leading developer of pion...

Product Service News

Twist Bioscience Enhances Agricultural Genomics with the Launch of its Ultra High-Throughput Library Preparation Solution

Published Mon, Feb 5 2024 1:00 PM UTC

Twist Bioscience Corporation (NASDAQ: TWST), an industry trailblazer renowned for their success in offering high-quality synthetic DNA via a silicon platform, has officially announced early access to their groundbreaking Twist Flex Prep Ultra High-Throughput (UHT) Kit. Designed to enable unparalleled throughput at a significantly reduced cost compared to existing market solu...

Twist Bioscience Corporation

Twist Bioscience Corporation Surges with Record-breaking Earnings in Q1 2024!

As a Wall Street journalist, it is important to analyze the recent financial results of Twist Bioscience Corporation in the context of its overall business strategy and market positioning. The company reported a net shortfall of $43.008 million for the fiscal period ending December 31, 2023, which was higher than the previous year's figure of $41.824 million. Despite this, Twist Bioscience saw a significant increase in revenue, reaching $71.5 million in the first quarter of fiscal 2024, representing a 31.811% surge from the same period a year ago.
One key metric to consider is the level of inventories, which declined to $30.9 million compared to the previous quarter and the same period a year before. This decrease could be indicative of future demand and could potentially help improve the company's profitability in the coming quarters. Additionally, the level of accounts receivable has also declined to $35.4 million, potentially signaling a slowdown in demand as noted by some analysts.






 

Twist Bioscience's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com